Losartan renal
Pro Research Analysisby 
Searched over 200M research papers for "losartan renal"
Losartan and Renal Protection: Insights from Recent Research
Losartan in Diabetic Nephropathy
Renal Outcomes in Type 2 Diabetes
Losartan, an angiotensin-II-receptor antagonist, has shown significant renal benefits in patients with type 2 diabetes and nephropathy. A large-scale study involving 1513 patients demonstrated that losartan reduced the incidence of a doubling of serum creatinine by 25% and end-stage renal disease (ESRD) by 28% compared to placebo, over a mean follow-up of 3.4 years. Additionally, losartan significantly decreased proteinuria by 35%1. These findings highlight losartan's potential to slow the progression of renal disease in diabetic patients.
Acute GFR Changes and Long-term Renal Function
An interesting observation from the RENAAL trial was that an acute fall in estimated glomerular filtration rate (eGFR) during the initial phase of losartan treatment predicted a slower decline in long-term renal function. Patients who experienced a significant initial drop in eGFR had a slower rate of eGFR decline over time, suggesting that this initial response might be a favorable prognostic indicator2.
Economic Benefits
The economic evaluation of the RENAAL study revealed that losartan not only reduced the incidence of ESRD but also resulted in substantial cost savings. Patients treated with losartan experienced fewer days with ESRD, leading to a net savings of $3522 per patient over 3.5 years4. This underscores the cost-effectiveness of losartan in managing diabetic nephropathy.
Losartan in Non-Diabetic Renal Insufficiency
Optimal Dosing for Renoprotection
The Renoprotection of Optimal Antiproteinuric Doses (ROAD) study compared conventional and uptitrated doses of losartan in patients with chronic renal insufficiency. The study found that higher, individualized doses of losartan significantly reduced the risk of doubling serum creatinine, ESRD, or death by 53% compared to conventional doses. This suggests that optimizing losartan dosage can enhance its renoprotective effects5.
Comparison with Amlodipine
In a comparative study, losartan was found to be more effective than amlodipine in reducing proteinuria in patients with chronic kidney disease (CKD) and hypertension. Over a 12-month period, losartan significantly reduced urinary protein excretion, whereas amlodipine did not. This reduction in proteinuria was observed regardless of the level of blood pressure control achieved, indicating that losartan's benefits extend beyond its antihypertensive effects6.
Mechanistic Insights and Biomarkers
Dopaminergic and Renin-Angiotensin Systems
Research on the interplay between the renal dopaminergic system (RDS) and the renin-angiotensin system (RAS) has shown that losartan can prevent the imbalance induced by fructose overload, which is associated with insulin resistance and hypertension. Losartan normalized the levels of renal angiotensin II and dopamine, reduced pro-inflammatory and pro-fibrotic markers, and prevented renal damage. The study also proposed the l-dopa/dopamine index as a potential biomarker for renal dysfunction3.
Uric Acid Reduction
A post hoc analysis of the RENAAL trial indicated that losartan's ability to lower serum uric acid (SUA) levels contributed to its renoprotective effects. A reduction in SUA was associated with a decreased risk of renal events, suggesting that SUA may be a modifiable risk factor for renal disease7.
Conclusion
Losartan has demonstrated significant renoprotective effects in both diabetic and non-diabetic populations with renal insufficiency. Its benefits include reducing the progression to ESRD, lowering proteinuria, and providing economic savings. Mechanistic studies further elucidate its role in modulating renal hemodynamics and inflammatory pathways. These findings support the use of losartan as a key therapeutic agent in managing renal diseases.
Sources and full results
Most relevant research papers on this topic
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Losartan significantly reduces the risk of kidney damage and end-stage renal disease in patients with type 2 diabetes and nephropathy, while maintaining overall cardiovascular health.
RCT
Large Human Trial
Highly CitedAn acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.
Greater acute fall in glomerular filtration rate during losartan treatment predicts slower long-term decline in renal function.
RCT
Rigorous JournalHighly CitedLosartan prevents the imbalance between renal dopaminergic and renin angiotensin systems induced by fructose overload. l-Dopa/dopamine index as new potential biomarker of renal dysfunction.
Losartan effectively prevents the imbalance between the renin angiotensin and renal dopaminergic systems induced by fructose overload, preventing hypertension and kidney damage.
RCT
Animal StudyLosartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.
Losartan treatment in patients with type 2 diabetes and nephropathy reduced the incidence of end-stage renal disease and resulted in substantial cost savings.
RCTRigorous JournalHighly CitedRenoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.
Optimal antiproteinuric dosages of benazepril and losartan can safely improve renal outcomes in patients with chronic renal insufficiency without causing major adverse events.
RCTLarge Human TrialHighly CitedRenoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension--a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study.
Losartan reduces proteinuria in patients with chronic kidney disease and hypertension, potentially contributing to its renal protective benefit beyond blood pressure control.
RCTHighly CitedEffect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment: A Post Hoc Analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial
Losartan treatment lowers serum uric acid levels, which is associated with a reduced long-term renal risk and explains part of its renoprotective effect in patients with type 2 diabetes and nephropathy.
RCTLarge Human TrialRigorous JournalHighly CitedEffects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients.
Losartan maintains renal function and reduces TGF-beta1 levels, while amlodipine increases GFR and has opposite effects, potentially impacting chronic allograft nephropathy management.
RCTHighly CitedEfficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group.
Once-daily losartan effectively reduces blood pressure in hypertensive patients with chronic renal disease and is well-tolerated, even in those on hemodialysis.
RCTAliskiren combined with losartan in type 2 diabetes and nephropathy.
Aliskiren combined with losartan may have renoprotective effects in patients with hypertension, type 2 diabetes, and nephropathy, independent of its blood-pressure-lowering effect.
RCTLarge Human TrialHighly Cited